Danaher (DHR) Stock
Diversified science company for life sciences and diagnostics. Here's the price, business snapshot, and what's worth knowing about Danaher in August 2026.
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It’s Moving
Danaher gains as a smooth CEO handoff and steady guidance keep the long-term story intact
- Danaher shares were lifted by a fresh CEO transition, with Julie Sawyer Montgomery set to take over on October 1, a move investors read as continuity rather than disruption.
- The company also backed its existing guidance, helping calm nerves after second-quarter results that showed higher sales and earnings but still left questions around bioprocessing growth.
- Recent analyst commentary has stayed constructive, with a Barclays buy call and broader consensus pointing to confidence in Danaher’s long-term operating consistency despite near-term growth concerns.
Danaher gains as a smooth CEO handoff and steady guidance keep the long-term story intact
- Danaher shares were lifted by a fresh CEO transition, with Julie Sawyer Montgomery set to take over on October 1, a move investors read as continuity rather than disruption.
- The company also backed its existing guidance, helping calm nerves after second-quarter results that showed higher sales and earnings but still left questions around bioprocessing growth.
- Recent analyst commentary has stayed constructive, with a Barclays buy call and broader consensus pointing to confidence in Danaher’s long-term operating consistency despite near-term growth concerns.
About This Stock
Danaher
DHR
Current Price
$211.59
Potential 12 Month Profit
19.36%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Ticker
DHR
Market Cap
$148.68B
Potential 12 Month Profit
19.36%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Sixth Month Growth Performance
When is the next earnings date for Danaher (DHR)?
Danaher’s next earnings date is currently expected on October 20, 2026, based on the company’s typical quarterly reporting pattern. The report should cover third-quarter 2026 results. That date is an estimate rather than a formally confirmed release, but it aligns with the company’s recent schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher's stock, expecting its price to rise significantly to $258.7.
Financial Health
Danaher is performing well with strong revenues and cash flow, indicating solid financial stability.
Dividend
Danaher's dividend yield of 0.76% is low, indicating limited income potential for investors. If you invested $1000 you would be paid $7.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.